Phase 2 Study of Oral K201 for Prevention of AF Recurrence

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 300 participants.

Also called NCT01067833

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Sequel Pharmaceuticals, Inc (from the registry)
Registry
  • NCT NCT01067833
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01067833. Randomized; quadruple masking; primary purpose prevention. Start 2010-04 (registry gives no type); primary completion 2011-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study of Oral K201 for Prevention of AF Recurrence
Acronym
ARCTIC-AF
Intervention (Drug)
K201 Tablet
Intervention (Drug)
Placebo Tablet
Lead sponsor
Sequel Pharmaceuticals, Inc (class: industry)

Record details

Record id
cardio:ct-nct01067833
Content hash
c59228a0e61e46d51878c4685dfa2a7e4279f09d006a5454919bd8de52bc4bca